Granted Patent B2

US 12,383,510 · App. 18/581,460 · Granted Aug 12, 2025

Inventors: James Oliver (Raleigh, NC); Fotios Plakogiannis (Whitestone, NY); Tamanna Lather (Livingston, NY); Marina Borovinskaya (East Brunswick, NJ); Nisarg Modi (Plainview, NY); Rod L. Hartwig (Hamburg, NJ)

Assignee: Starton Therapeutics, Inc.

A61K9/7053A61K9/0053A61K9/7061A61K9/7069A61K31/5513A61K47/10A61K47/12A61K47/14A61K47/20A61K47/38A61P1/08

Abstract

Claims (23)

1. A composition, comprising:

an adhesive matrix comprising olanzapine in combination with a fatty alcohol, a fatty ester, or a combination thereof, wherein the composition is capable of achieving an average flux rate of olanzapine of at least 3 μg/cm 2 /hr continuously throughout a period of at least 3 days after administration of the composition.

2. The composition of claim 1 , wherein the composition further comprises an emulsifier or a penetration enhancer.

3. The composition of claim 2 , wherein the emulsifier is a glycerol ester.

4. The composition of claim 3 , wherein the glycerol ester is selected from the group consisting of glycerol monooleate, glyceryl monotallate, and glyceryl trioleate.

5. The composition of claim 2 , wherein the penetration enhancer is selected from dimethyl sulfoxide and n-dodecylcaprolactam (Azone).

6. The composition of claim 1 , wherein a molar amount of olanzapine is selected to deliver between 1-20 mg olanzapine in 24 hours when the composition is applied to skin.

7. The composition of claim 1 , wherein the adhesive matrix comprises a fatty alcohol and a fatty ester.

8. The composition of claim 7 , wherein the fatty alcohol is myristyl alcohol.

9. The composition of claim 7 , wherein the fatty ester is isopropyl palmitate.

10. The composition of claim 1 , wherein the adhesive matrix comprises a polyvinylpyrrolidone.

11. The composition of claim 10 , wherein the polyvinylpyrrolidone is selected from a cross-linked polyvinylpyrrolidone and a copolymer of polyvinylpyrrolidone.

12. The composition of claim 1 , wherein the adhesive matrix further comprises a pressure-sensitive adhesive.

13. The composition of claim 12 wherein the pressure-sensitive adhesive is an acrylate copolymer.

14. A transdermal device, comprising the composition according to claim 1 .

15. A composition, comprising:

(i) at least about 40 wt. % of a pressure-sensitive adhesive;

(ii) between about 3-15 wt. % of a fatty acid ester, a fatty alcohol, or a combination thereof; and

(iii) between about 5-20 wt. % olanzapine; wherein the composition is capable of achieving an average flux rate of olanzapine of at least 3 μg/cm 2 /hr continuously throughout a period of at least 3 days after application of the composition to the skin.

16. The composition of claim 15 , wherein the pressure-sensitive adhesive is an acrylate copolymer.

17. The composition of claim 15 , wherein the fatty acid ester is isopropyl palmitate.

18. The composition of claim 15 , further comprising polyvinylpyrrolidone, ethyl cellulose, silicone dioxide, or a combination thereof.

19. The composition of claim 15 , wherein the fatty alcohol is myristyl alcohol.

Assignments (1)

Continuity (6)

References Cited (17)